サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：認知症性運動障害治療症候群の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 治療に使用される薬剤別、地域別
市場調査レポート
商品コード
1410525

認知症性運動障害治療症候群の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 治療に使用される薬剤別、地域別

Treatment Syndromes Dementia Movement Disorders Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日: | 発行: Fairfield Market Research | ページ情報: 英文 82 Pages | 納期: 2～5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
認知症性運動障害治療症候群の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 治療に使用される薬剤別、地域別
出版日: 2024年01月04日
発行: Fairfield Market Research
ページ情報: 英文 82 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

世界の認知症や運動障害に関連する症候群の治療薬の市場規模、近年著しい成長を遂げています。精神疾患の広範なカテゴリーである認知症と、パーキンソン病を含む運動障害は、世界中の患者と介護者の双方にとって大きな課題となっています。最近のデータによると、パーキンソン病などの運動障害を患う人の約80％が最終的に認知障害を発症しており、効果的な治療法の必要性がさらに強調されています。

世界中で高齢化が進んでいることが、認知症患者数増加の原動力となっています。この症例の急増により、ヘルスケアプロバイダーは在宅ケアサービス、成人デイケアサービス、心理療法、薬物療法、認知症末期患者に合わせた医療機器など、さまざまな解決策を模索しています。緩和ケア病棟も、患者とその家族の要望に応えて大きく成長しています。

しかし、認知症や運動障害を患う人々の負担を軽減するための努力にもかかわらず、いくつかの課題が残っています。これらの課題には、厳しい規制の枠組み、医薬品承認プロセスにおける官僚的なハードル、研究開発のための資金不足、効果的な治療管理法を見つけるための継続的な闘争などが含まれます。これらの疾患を治療するためにデザインされた薬剤のほとんどが第III相試験をパスできず、実行可能な治療法を見つけるための困難な障害となっていることは注目に値します。

当レポートでは、世界の認知症性運動障害治療症候群市場について調査し、市場の概要とともに、治療に使用される薬剤別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の治療症候群、認知症、運動障害市場の見通し、2018年～2031年

  • 世界の認知症性運動障害治療症候群市場の見通し、進行性認知症の治療に使用される薬剤別、金額（10億米ドル）、2018年～2031年
  • 世界の認知症性運動障害治療症候群市場の見通し、その他の神経学的異常を伴う進行性認知症の治療に使用される薬剤別、金額（10億米ドル）、2018年～2031年
  • 世界の認知症性運動障害治療症候群市場の見通し、運動障害症候群の治療に使用される薬剤別、金額（米国米ドル）、2018年から2031年
  • 世界の治療症候群、認知症、運動障害市場の見通し、地域別、金額（10億米ドル）、2018年～2031年

第4章 北米の認知症性運動障害治療症候群市場の見通し、2018年～2031年

第5章 欧州の認知症性運動障害治療症候群市場の見通し、2018年～2031年

第6章 アジア太平洋の認知症性運動障害治療症候群市場の見通し、2018年～2031年

第7章 ラテンアメリカの認知症性運動障害治療症候群市場の見通し、2018年～2031年

第8章 中東・アフリカの認知症性運動障害治療症候群市場の見通し、2018年～2031年

第9章 競合情勢

  • 運動障害症候群の治療に使用される薬剤別vsその他の神経学的異常を伴う進行性認知症の治療に使用される薬剤別ヒートマップ
  • 企業の市場シェア分析、2023年
  • 競争力ダッシュボード
  • 企業プロファイル
    • F. Hoffmann-La Roche, Ltd.
    • Baxter
    • Novartis AG
    • Merck & Co., Inc.
    • Sanofi
    • Pfizer, Inc.
    • Valeant Pharmaceuticals International, Inc.
    • AstraZeneca GmbH
    • Abbott Laboratories, Inc.
    • Bristol-Myers Squibb Company

第10章 付録

目次

Leading Pharmaceutical Companies Aim to Address Rising Incidence of Cognitive Defects

The global market for the treatment of syndromes related to dementia and movement disorders has witnessed remarkable growth in recent years, as the number of individuals affected by these conditions continues to rise. Dementia, a broad category of mental illnesses, and movement disorders, including Parkinson's disease, have presented significant challenges for both patients and caregivers worldwide. According to recent data, approximately 80% of people with movement disorders such as Parkinson's ultimately develop cognitive defects, further emphasizing the need for effective treatments.

Key Market Dynamics:

The increasing aging population across the globe is a driving force behind the rising number of dementia cases. This surge in cases has prompted healthcare providers to explore a range of solutions, including home care services, adult day care services, psychological therapies, medication, and medical devices tailored for last-stage dementia patients. Palliative care units are also witnessing significant growth in response to the demands of patients and their families.

However, despite the collective efforts to ease the burden on those affected by dementia and movement disorders, several challenges persist. These challenges include a stringent regulatory framework, bureaucratic hurdles in the drug approval process, insufficient funding for research and development, and the ongoing struggle to find effective therapeutic management methods. It is noteworthy that most drugs designed to treat these conditions fail to pass Phase III testing, creating a daunting roadblock in the quest to find viable treatments.

Regional Analysis:

Geographically, the North America region is expected to maintain its dominance in the global market for the treatment of syndromes associated with dementia and movement disorders. This dominance is driven by the growing aging population and the increasing incidence of neurodegenerative diseases. Over the next six years, the Asia region is also projected to experience higher growth rates in this market, signaling the need for innovative solutions to meet the rising demand.

Key Market Players:

Major companies at the forefront of the global market for the treatment of dementia and movement disorders include Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Valeant Pharmaceutical International, and Pfizer, among others. These industry leaders are dedicated to developing innovative treatments to address the complex challenges presented by these debilitating conditions.

Segment Analysis:

The global market for the treatment of syndromes related to dementia and movement disorders is categorized based on the drugs used for treatment, including progressive dementia, movement disorders, and progressive dementia with certain other neurological abnormalities. These segments encompass drugs tailored for specific conditions, diseases-based therapeutics, and those designed to address associated neurological abnormalities.

As the global community grapples with the growing burden of dementia and movement disorders, the healthcare and pharmaceutical industries are committed to advancing research and delivering effective treatments that enhance the quality of life for affected individuals and their families.

By Drugs Used to Treatment Progressive Dementia

  • Diseases Based Therapeutics Under Progressive Dementia
  • Drugs for Progressive Dementia

By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities

  • Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
  • Drugs for Progressive Dementia

By Drugs Used to Treat Movement Disorder Syndrome

  • Diseases Based Therapeutics Under Movement Disorder Syndrome
  • Drugs for Movement Disorder Syndrome

By Region

  • North America
  • Europe
  • Asia

Table of Contents

1. Executive Summary

  • 1.1. Global Treatment Syndromes Dementia Movement Disorders Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

  • 3.1. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
      • 3.1.1.2. Drugs for Progressive Dementia
  • 3.2. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
      • 3.2.1.2. Drugs for Progressive Dementia
  • 3.3. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
      • 3.3.1.2. Drugs for Movement Disorder Syndrome
  • 3.4. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

  • 4.1. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
      • 4.1.1.2. Drugs for Progressive Dementia
  • 4.2. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
      • 4.2.1.2. Drugs for Progressive Dementia
  • 4.3. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
      • 4.3.1.2. Drugs for Movement Disorder Syndrome
  • 4.4. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 4.4.1.2. U.S. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 4.4.1.3. U.S. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 4.4.1.4. Canada Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 4.4.1.5. Canada Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 4.4.1.6. Canada Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

  • 5.1. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
      • 5.1.1.2. Drugs for Progressive Dementia
  • 5.2. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
      • 5.2.1.2. Drugs for Progressive Dementia
  • 5.3. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
      • 5.3.1.2. Drugs for Movement Disorder Syndrome
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.2. Germany Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.3. Germany Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 5.4.1.4. U.K. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.5. U.K. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.6. U.K. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 5.4.1.7. France Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.8. France Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.9. France Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 5.4.1.10. Italy Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.11. Italy Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.12. Italy Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 5.4.1.13. Turkey Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.14. Turkey Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.15. Turkey Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 5.4.1.16. Russia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.17. Russia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.18. Russia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
      • 6.1.1.2. Drugs for Progressive Dementia
  • 6.2. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
      • 6.2.1.2. Drugs for Progressive Dementia
  • 6.3. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
      • 6.3.1.2. Drugs for Movement Disorder Syndrome
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 6.4.1.2. China Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 6.4.1.3. China Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 6.4.1.4. Japan Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 6.4.1.5. Japan Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 6.4.1.6. Japan Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 6.4.1.7. South Korea Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 6.4.1.8. South Korea Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 6.4.1.9. South Korea Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 6.4.1.10. India Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 6.4.1.11. India Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 6.4.1.12. India Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

  • 7.1. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
      • 7.1.1.2. Drugs for Progressive Dementia
  • 7.2. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
      • 7.2.1.2. Drugs for Progressive Dementia
  • 7.3. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
      • 7.3.1.2. Drugs for Movement Disorder Syndrome
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 7.4.1.2. Brazil Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 7.4.1.3. Brazil Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 7.4.1.4. Mexico Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 7.4.1.5. Mexico Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 7.4.1.6. Mexico Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 7.4.1.7. Argentina Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 7.4.1.8. Argentina Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 7.4.1.9. Argentina Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
      • 8.1.1.2. Drugs for Progressive Dementia
  • 8.2. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
      • 8.2.1.2. Drugs for Progressive Dementia
  • 8.3. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
      • 8.3.1.2. Drugs for Movement Disorder Syndrome
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 8.4.1.2. GCC Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 8.4.1.3. GCC Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 8.4.1.4. South Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 8.4.1.5. South Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 8.4.1.6. South Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 8.4.1.7. Egypt Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 8.4.1.8. Egypt Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 8.4.1.9. Egypt Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 8.4.1.10. Nigeria Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 8.4.1.11. Nigeria Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 8.4.1.12. Nigeria Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Drugs Used to Treat Movement Disorder Syndrome vs By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities Heat map
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. F. Hoffmann-La Roche, Ltd.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Baxter
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Novartis AG
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Merck & Co., Inc.
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Sanofi
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Pfizer, Inc.
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Valeant Pharmaceuticals International, Inc.
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. AstraZeneca GmbH
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Abbott Laboratories, Inc.
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Bristol-Myers Squibb Company
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations